

1. Abubaker, K., Luwor, R. B., Escalona, R., **McNally, O.**, **Quinn, M. A.**, Thompson, E. W., Findlay, J. K. and **Ahmed, N.** (2014). Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. *Front Oncol* 4, 75.
2. Abubaker, K., Luwor, R. B., Zhu, H., **McNally, O.**, **Quinn, M. A.**, Burns, C. J., Thompson, E. W., Findlay, J. K. and **Ahmed, N.** (2014). Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. *BMC Cancer* 14, 317.
3. Ahmed, N., Abubaker, K. and Findlay, J. K. (2014). Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. *Mol Aspects Med* 39, 110-25.
4. Anuradha, S., Webb, P. M., Blomfield, P., Brand, A. H., Friedlander, M., Leung, Y., Obermair, A., Oehler, M. K., **Quinn, M.**, Steer, C. et al. (2014). Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. *Med J Aust* 201, 283-8.
5. Au-Yeung, G. Webb, P. M. DeFazio, A. Fereday, S. Bressel, M. Mileskin, L (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). *Gynecol Oncol* 133(1): 16-22.
6. Brennan, D. J., Hackethal, A., Metcalf, A. M., Coward, J., Ferguson, K., Oehler, M. K., **Quinn, M. A.**, Janda, M., Leung, Y., Freemantle, M. et al. (2014). Serum HE4 as a prognostic marker in endometrial cancer--a population based study. *Gynecol Oncol* 132, 159-65.
7. Brotherton, J. M. and **C. D. Wrede** (2014). Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: what do you need to know? *Aust N Z J Obstet Gynaecol* 54(4): 393-394.
8. Brownfoot, F. C., Hickey, M., Ang, W. C., **Arora, V.** and **McNally, O.** (2014). Complex atypical hyperplasia of the endometrium: differences in outcome following conservative management of pre- and postmenopausal women. *Reprod Sci* 21, 1244-8.
9. Buchanan, D. D., Tan, Y. Y., Walsh, M. D., Clendenning, M., Metcalf, A. M., Ferguson, K., Arnold, S. T., Thompson, B. A., Lose, F. A., Parsons, M. T., Walters, R. J., Pearson, S. A., Cummings, M., Oehler, M. K., Blomfield, P. B., **Quinn, M. A.**, Kirk, J. A., Stewart, C. J., Obermair, A., Young, J. P., Webb, P. M. & Spurdle, A. B. 2014. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. *J Clin Oncol*, 32, 90-100.
10. Cade, T. J., **Quinn, M. A.**, Rome, R. M. and Polyakov, A. (2014). Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma. *Aust N Z J Obstet Gynaecol* 54, 453-6.

11. du Bois, A., A. Floquet, **Australian and New Zealand Gynecological Oncology Group** et al. (2014). Incorporation of pazopanib in maintenance therapy of ovarian cancer. *J Clin Oncol* 32(30): 3374-3382.
12. Friedlander, M. L., M. Stockler, **Australian and New Zealand Gynecological Oncology Group** et al. (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. *Int J Gynecol Cancer* 24(5): 857-864.
13. Gao B, Russell A, Beesley J, Chen XQ, Healey S, Henderson M, Wong M, Emmanuel C, Galletta L, Johnatty SE, Bowtell D; **Australian Ovarian Cancer Study Group**, Haber M, Norris M, Harnett P, Chenevix-Trench G, Balleine RL, deFazio A. (2014) Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *Sci Rep*. 2014 May 9;4:4669. doi: 10.1038/srep04669.
14. Harter, P., D. Gershenson, **Australian and New Zealand Gynecological Oncology Group** et al. (2014). Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). *Int J Gynecol Cancer* 24(9 Suppl 3): S5-8.
15. Hawkes, A. L., **Quinn, M.**, Gebiski, V., Armes, J., Brennan, D., Janda, M. and Obermair, A. (2014). Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device +/- metformin +/- weight loss in endometrial cancer (feMME) trial. *Contemp Clin Trials* 39, 14-21.
16. Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; **Australian Ovarian Cancer Study Group**, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ. (2014) ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. *J Natl Cancer Inst*. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.
17. Hensley, M. L. Barrette, B. A. Baumann, K. Gaffney, D. **Hamilton, A. L.**, et al. (2014). Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. *Int J Gynecol Cancer* 24(9 Suppl 3): S61-66.
18. Leitao, M. M., Jr. Cheng, X. **Hamilton, A. L.** Siddiqui, N. A. et al. (2014). "Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas. *Int J Gynecol Cancer* 24(9 Suppl 3): S117-122.
19. Madondo, M. T., Tuyraerts, S., Turnbull, B. B., Vanderstraeten, A., Kohrt, H., Narasimhan, B., Amant, F., **Quinn, M.** and Plebanski, M. (2014). Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. *J Transl Med* 12, 179.
20. Mitchell, P. L., **Quinn, M. A.**, Grant, P. T., Allen, D. G., Jobling, T. W., White, S. C., Zhao, A., Karanikas, V., Vaughan, H., Pietersz, G. et al. (2014). A phase 2, single-

- arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. *J Immunother Cancer* 2, 16.
21. Mutch, D., Denny, L. and **Quinn, M.** (2014). Hereditary gynecologic cancers. *Int J Gynaecol Obstet* 124, 189-92.
  22. Pautier, P. Nam, E. J. Provencher, D. M. **Hamilton, A. L.** Mangili, G. Siddiqui, N. A. Westermann, A. M. Reed, N. S. Harter, P. Ray-Coquard, I.. (2014). Gynecologic Cancer InterGroup (GCIg) consensus review for high-grade undifferentiated sarcomas of the uterus. *Int J Gynecol Cancer* 24(9 Suppl 3): S73-77.
  23. Phillips, S., Garland, S. M., Tan, J. H., **Quinn, M. A.** and Tabrizi, S. N. (2014). Comparison of the Roche Cobas® 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia. *Journal of Clinical Virology* 62, 63-65.
  24. Prat, J. **FIGO Committee** on Gynecologic Oncology (2014). "Staging classification for cancer of the ovary, fallopian tube, and peritoneum." *Int J Gynaecol Obstet* 124(1): 1-5.
  25. Rowlands, I. J., Beesley, V. L., Janda, M., Hayes, S. C., Obermair, A., **Quinn, M. A.**, Brand, A., Leung, Y., McQuire, L. and Webb, P. M. (2014). Quality of life of women with lower limb swelling or lymphedema 3-5years following endometrial cancer. *Gynecol Oncol.*
  26. **Scott, C. L.**, H. J. Mackay, et al. (2014). Patient-derived xenograft models in gynecologic malignancies. *Am Soc Clin Oncol Educ Book*: e258-266.
  27. Sultana F, English DR, Simpson JA, Brotherton JM, Drennan K, Mullins R, Heley S, **Wrede CD**, Saville M, Gertig DM. (2014) Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia." *BMC Cancer* 14: 207.
  28. Stafford, L., Judd, F., Gibson, P., Komiti, A., **Quinn, M.** and Mann, G. B. (2014). Comparison of the Hospital Anxiety and Depression Scale and the Center for Epidemiological Studies Depression Scale for detecting depression in women with breast or gynecologic cancer. *Gen Hosp Psychiatry* 36, 74-80.
  29. Stafford, L. and Miller, B. (2014). Should Every Woman with Gynecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction? In *Controversies in the Management of Gynecological Cancers*, (ed. J. A. Ledermann C. L. Creutzberg and **M. A. Quinn**), pp. 297-308: Springer London.
  30. Topp, M. D., Hartley, L., Cook, M., **Heong, V.**, Boehm, E., McShane, L., Pyman, J., **McNally, O.**, **Ananda, S.**, Harrell, M. et al. (2014). Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. *Mol Oncol.*
  31. Van Cromvoirt, S. M., Thomas, C. M., **Quinn, M. A.**, **McNally, O. M.** and Bekkers, R. L. (2014). Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve. *Gynecol Oncol.*
  32. Vergote, I. Oaknin, A. Baurain, J. F. **Ananda, S.** Wong, S. Su, X. Wu, B. Zhong, Z. Warner, D. Casado, A. (2014). A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. *Eur J Cancer* 50(14): 2408-2416.

33. Vergote I, Schilder RJ, Pippitt C, Wong S, Gordon S, Scudder S, Kridelka F, Dirix L, Leach J, **Ananda S**, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham JM. (2014) A Phase 1b Study of Trebananib in Combination With Pegylated Liposomal Doxorubicin or Topotecan in Women With Recurrent Platinum Resistant or Partially Platinum Sensitive Ovarian Cancer. *Gynecol Oncol*.

## BOOKS

Controversies in Gynaecological Cancer Lederman, J L, Creutzberg C L, **Quinn MA** Springer 2014

1. When should surgery be performed for the first-line treatment of advanced ovarian cancer RajGKA, Hook J, Lederman JL, Quinn MA in *Controversies in Gynaecological Oncology* Lederman, JL Creutzberg CL, Quinn MA Springer 135-144, 2014
2. What is the value of lymphadenectomy in early ovarian cancer? Mahner S, Pfisterer J, Raj GKA, Quinn MA in *Controversies in Gynaecological Oncology* Lederman, JL Creutzberg CL, Quinn MA Springer, 165-174, 2014